"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-07

Study Completion Date

2020-11-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase II prospective, randomized, double-blind, placebo controlled and comparative clinical study evaluating hydrogel scar-management modalities for effective management of hyperproliferative scars and keloids.

This is a double-blinded study, which means that neither the evaluating physician nor the subject will know which treatment is administered.

Group selection and assignment will be made at random, with a 2 in 5 chance of receiving a market-approved therapy, and 1 in 5 chance of receiving the placebo. Subjects assigned the placebo-moisturizer will receive a standard hypoallergenic dermatological hydrating cream base. Subjects assigned the silicone gel, will receive a commercially available, active comparator.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars

NCT00754247

Keloid Hypertrophic Scar Cicatrix, Hypertrophic

COMPLETED PHASE4

Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars

NCT06751433

Acceptability Study Real-use Conditions Safety and Efficacy +3 more

RECRUITING PHASE1/PHASE2

Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars

NCT01861119

Hypertrophic or Keloid Scars

COMPLETED PHASE3

Comparative Study Between Intralesional Corticosteroid Injection Alone and Combined Intralesional Corticosteroid Injection With Either Long-pluse Nd YAG or Erbium Yag for Treating Hypertrophic or Keloid Scars

NCT07263100

Hypertrophic Scar Keloid Laser

COMPLETED NA

Effect of Silicone Gel Versus Contractubex Phonophoresis for Post-burn Hypertrophic Scars

NCT03777891

Hypertrophic Scar

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Phase II prospective, randomized, double-blind, placebo controlled and comparative clinical study evaluating hydrogel scar-management modalities for effective management of hyperproliferative scars and keloids. Unlike raised and, or hyperproliferative scars that result from aberrant wound healing, keloids are the result of inherited genetic mutations in a variety of proteins essential to orchestrated wound repair. Whereas hyperproliferative scars may have shared similar abnormalities throughout the repair of a primary injury, they are not predictors of subsequent scarring following scar revision. Keloids on the other hand will return upon excision, and in some cases larger in size than the excised scar tissue. Current treatment options for keloids as well as hypertrophic scars include intralesional corticosteroids, silicone gel sheeting, compression, surgery and adjuvants to surgery, including radiation and cryotherapy.

Onion skin extract, silicone, and a variety of over-the-counter selfcare product options are available for patients with keloids and hypertrophic scars. Despite market approval, robust efficacy data to substantiate product claims is scarce. At best, comparative studies have been able to demonstrate significance between modalities/products. With only a limited number of investigator initiated studies with scar-patients the advancement in this niche, yet expansive, medical sector has been incremental across decades of research. This study is being undertaken to investigate the efficacy and safety of a FS2- moisturizer, and two market-approved scar topical therapies. The FS2- moisturizer is claimed to be substantially equivalent or superior to market approved Onion skin extract (Mederma), and silicone gel (Kelo-Cote)intended to manage and improve hyperproliferative closed scars. The study builds upon a recent study that investigated safety and efficacy of a petrolatum lotion vs. onion-extract gel vs. placebo in subjects with hypertrophic scars and keloids. There two (2) Study Arms and five (5) Treatment Groups. Treatment Groups consist of: placebo moisturizer cream base, Onion skin extract (Mederma), FS2-moisturizer formulations, silicone gel (Kelo-Cote), and an FS2-silicone gel.

This is a double-blinded study, which means that neither the evaluating physician nor the subject will know which treatment is administered. A separate study team member will administer the treatment, as well as answer questions and discuss any problems prior to starting, and for the duration of, the study.

Subjects will be assigned a Treatment Group from those listed above. Group selection and assignment will be made at random, with a 2 in 5 chance of receiving a market-approved therapy, and 1 in 5 chance of receiving the placebo. Subjects assigned the placebo-moisturizer will receive a standard hypoallergenic dermatological hydrating cream base. Subjects assigned the silicone gel, will receive a commercially available, active comparator.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scar Keloid Hypertrophic Scar Cicatrix

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study consists of five Treatments across two study Arms of which include a placebo, a 510(k) market-approved "Active" comparator with and without FS2, and two cosmetic, moisturizer formulation variants that have not demonstrated therapeutic efficacy, but are hypothesized to improve the appearance of scar-prone wounds once healed. The Placebo moisturizer serves as the negative control, whereas the silicone gel serves both purposes as a negative control for the FS2 incorporated silicone gel and active comparator for both FS2 silicone gel and the moisturizing products.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

This is a double-blinded study, which means that neither the evaluating physician nor the subject will know which treatment is administered. A separate study staff member will administer the treatment, as well as answer questions and discuss any problems prior to starting, and for the duration of, the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FS2 Emulsion Moisturizer

The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.

Group Type EXPERIMENTAL

Placebo Cream Base Emulsion Moisturizer

Intervention Type OTHER

Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days

FS2 Emulsion Moisturizer

Intervention Type OTHER

Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days

Active Comparator Onion Skin Extract Gel (Mederma)

Intervention Type OTHER

Topical onion skin extract gel (Mederma) applied b.d. for 120 days

Active Comparator + FS2 Emulsion Moisturizer

The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.

Group Type EXPERIMENTAL

Active Comparator Silicone Gel (Kelo-Cote)

Intervention Type OTHER

Topical silicone gel (Kelo-Cote) applied b.d. for 120 days

Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer

Intervention Type OTHER

Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo Cream Base Emulsion Moisturizer

Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days

Intervention Type OTHER

FS2 Emulsion Moisturizer

Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days

Intervention Type OTHER

Active Comparator Onion Skin Extract Gel (Mederma)

Topical onion skin extract gel (Mederma) applied b.d. for 120 days

Intervention Type OTHER

Active Comparator Silicone Gel (Kelo-Cote)

Topical silicone gel (Kelo-Cote) applied b.d. for 120 days

Intervention Type OTHER

Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer

Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female
2. Adult, Senior (\>18 years of age)
3. Healthy or medically stable
4. Keloid or hypertrophic scar
5. Willing and able to follow study requirements
6. Etiology and clinical assessment of the scar indicate that it could benefit from the study treatments

Exclusion Criteria

1. Subjects who are medically unstable
2. Subjects who are expected to be medically unstable for the duration of the study period and an additional 1-month thereafter
3. Pregnant subjects, or those attempting to become pregnant
4. Subjects with known immunosuppression or immunosuppressive illness
5. Subjects with uncontrolled diabetes or autoimmune disorders
6. Subjects with known sensitivity to ingredients in the test-treatment products
7. Subjects who are enrolled in another scar study and/or plan to receive or are receiving scar treatments other than study treatment during the trial period
8. Subjects who have received scar treatment, including any investigational treatment, within one month of the first day of study treatment
9. Subjects with any skin conditions or taking any medications that may interfere with the study medication
10. Subjects who had any clinical evidence of severe ongoing or prolonged depression, mental illness, and/or who has demonstrated evidence of drug abuse
11. Any other diagnosis, condition, physical or geographical limitation that may render, or increases the likelihood of rendering, the Subject unable to complete the entire study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No